Apollo Hospitals Enterprise Ltd.
Pharma · NSE
52-week range
₹6,660 – ₹8,115
From 52w high
-0.2%
RSI (14)
69.3
vs SMA 50 / 200
↑ 50 · ↑ 200
Apollo Hospitals Enterprise trades at ₹8,097, up 15.8% over the past year and 13.9% over the past three months, sitting 6.3% above its 50-DMA and 8.3% above its 200-DMA. The trailing PE of 64.6 (forward PE 48.7) reflects elevated market expectations, supported by a reported 5-year earnings CAGR of 35% and revenue CAGR of 17.2%, though debt-to-equity has risen to 83.6 and the quality score of 42/100 sits third among six sector peers.
- ✓5-year earnings growth of 35% and revenue growth of 17.2% CAGR indicate sustained top and bottom-line expansion over the medium term
- ✓Current price of ₹8,097 is above both the 50-DMA (₹7,615) and 200-DMA (₹7,477), reflecting broad-based trend participation over multiple timeframes
- ✓Forward PE of 48.7 represents a 24.6% compression from the trailing PE of 64.6, suggesting the market anticipates meaningful near-term earnings acceleration
- ✓Analyst mean rating of 1.39 across 29 analysts (1–5 scale, lower = more constructive) indicates a concentrated skew toward the constructive end of coverage
- ✗Debt-to-equity of 83.6 with a rising debt trend is a structural concern; FCF was positive in only 4 of the observed fiscal years, limiting internal funding capacity
- ✗ROE data is unavailable for APOLLOHOSP, making it impossible to assess capital efficiency against the 35% earnings growth claim — a gap that undermines quality-score confidence
- ✗Quality score of 42/100 ranks third of six in the Pharma/Hospital peer group; MAXHEALTH (54) and SUNPHARMA (50) score meaningfully higher
- ✗Profit margin of 7.44% is modest for a premium hospital network and leaves limited buffer if operating costs, interest expenses, or occupancy pressures intensify
- ·Third-party media outlets published directional trading calls on APOLLOHOSP in late April and early May 2026, including specific price targets; these are broker or journalist views and do not reflect VivaTrades analysis
- ·An options chain quote for the May 2026 ₹8,050 call strike appeared in the news feed, reflecting active derivatives market participation at current price levels
- ·The stock has retraced only 0.22% from its 52-week high, reaching this proximity after a 13.9% three-month rally — the nearest identified support levels are ₹7,562 and ₹7,476, approximately 6–8% below current price
- ?Does the 35% 5-year earnings CAGR reflect a structural shift in hospital economics (pricing power, occupancy, Apollo 24/7 digital traction) or a recovery from pandemic-depressed baselines that is unlikely to repeat?
- ?At a D/E of 83.6 with rising debt, how is Apollo funding its capacity expansion, and what is the interest coverage ratio relative to operating cash flow trends?
- ?Given that FCF was positive in only 4 of the observable years, to what extent is the forward PE of 48.7 dependent on a step-change in free cash generation that has not yet appeared in historical data?
- ?How does Apollo's hospital-segment margin profile compare to Max Healthcare (quality score 54 vs Apollo's 42), and what explains the quality-score gap despite Apollo's higher earnings growth rate?
PE
64.6
Forward PE
48.7
ROE
—
Profit margin
+7.4%
D/E
83.61
Dividend yield
+0.3%
Quality score
42/100
ROE 5y above 15%
2/5 yrs
FCF 5y positive
4/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 10 May 2026.